Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
National Institutes of Health (NIH)
Maximum funding amount: $250,000
Project duration: Up to 2 years
To support time-sensitive ancillary studies related to ongoing clinical projects.
Enhance scientific understanding of diseases within the NIAMS portfolio.
NIH and its associated institutes
Research community and patients involved in clinical studies
Eligible organization types include: Higher Education Institutions, Nonprofits, For-Profit Organizations, Local Governments, State Governments, County Governments, City or Township Governments, Indian/Native American Tribal Governments.
Non-domestic (non-U.S.) entities are not eligible to apply.
Organizations must be based in the U.S. or its territories.
Non-domestic components of U.S. organizations are not eligible.
Projects must be ancillary to ongoing clinical projects.
Must leverage existing resources from parent projects.
Direct costs are limited to $400,000 over a two-year period.
No more than $250,000 in direct costs in any single year.
Application due date: December 5, 2025.
Open date for submissions: March 9, 2025.
No restrictions on prior grant funding mentioned.
Applications must include a letter of approval from the parent study leadership.
Resource Sharing Plan and Data Management and Sharing Plan required.
Applications will be evaluated based on significance, innovation, rigor, and feasibility.
Applications will undergo an accelerated peer review process.
Preference will be given to innovative projects with high potential impact.
Ancillary studies must not interfere with the parent project.
Applications that do not demonstrate the need for expedited review will be considered non-responsive.
Encourages collaboration between basic and clinical investigators.
Applications leveraging existing clinical projects may have a competitive advantage.
Demonstrating the time-sensitive nature of the proposed study.
Submitting non-responsive applications.
Engage with NIAMS Program Directors prior to submission.
Highlight innovative aspects and potential impact in the application.